Vistagen Receives Notice From European Patent Office Of Intention To Grant Patent For AV-101 To Treat Neuropathic Pain
Portfolio Pulse from Benzinga Newsdesk
Vistagen Therapeutics (NASDAQ: VTGN) is set to receive a patent from the European Patent Office for AV-101, a treatment for neuropathic pain. Preclinical studies show AV-101 has effects similar to gabapentin but with fewer side effects. Phase 1 clinical trials indicate AV-101 is well-tolerated with no significant adverse events compared to placebo. The patent will extend until at least 2034, enhancing Vistagen's global patent portfolio. The company is seeking strategic collaborations to advance AV-101's clinical development and commercialization. The FDA has granted Fast Track designation for AV-101 as a non-opioid treatment for neuropathic pain.
December 27, 2023 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vistagen is poised to receive a European patent for AV-101, a potential non-opioid treatment for neuropathic pain, with positive preclinical and Phase 1 results. The patent strengthens their portfolio and the company is looking for strategic partners.
The notice of intention to grant a patent for AV-101 by the EPO is a significant positive development for Vistagen, as it not only extends the company's intellectual property protection but also validates the therapeutic potential of AV-101. The positive preclinical and Phase 1 clinical data further support the drug's profile, and the FDA's Fast Track designation underscores its potential in the market. These factors are likely to be viewed positively by investors and could lead to an increase in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100